Multiple myeloma bone marrow niche

Current Pharmaceutical Biotechnology

Volumn 10, Issue 3, 2009, Pages 335-346

  Basak, Grzegorz Wladyslaw ^a,b   Srivastava, Anand S ^c   Malhotra, Rakesh ^a   Carrier, Ewa ^a,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

^d School of Public Health ^*  (United States)

Author keywords

Bone marrow; Microenvironment; Multiple myeloma; Niche

Indexed keywords

ANTINEOPLASTIC AGENT; BORTEZOMIB; DEXAMETHASONE; FIBRONECTIN; HYALURONIC ACID; LENALIDOMIDE; MULTIDRUG RESISTANCE PROTEIN; SYNDECAN 1; THALIDOMIDE;

ADIPOCYTE; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; BONE MARROW; BONE REMODELING; CARCINOGENESIS; CELL ACTIVITY; CELL DIFFERENTIATION; CELL INTERACTION; CELL MATURATION; CELL TYPE; DENDRITIC CELL; DRUG MECHANISM; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; HEMATOPOIETIC STEM CELL; HUMAN; MULTIPLE MYELOMA; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROTEIN EXPRESSION; REVIEW; STROMA CELL; TARGET CELL; ANIMAL; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ADIPOCYTES; ANIMALS; BONE MARROW; DENDRITIC CELLS; ENDOTHELIAL CELLS; EXTRACELLULAR MATRIX; HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; STROMAL CELLS;

EID: 65949095894     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920109787847493     Document Type: Review

References (101)

1. Li, H.; Fan, X. and Houghton, J. (2007) Tumor microenvironment: the role of the tumor stroma in cancer. J. Cell Biochem., 101, 805-15.
2. Zhou, J.; Mauerer, K.; Farina, L. and Gribben, J.G. (2005) The role of the tumor microenvironment in hematological malignancies and implication for therapy. Front Biosci., 10, 1581-96.
3. Hillman, R.S. K.A. A, H.M. R. Hematology in clinical practice: a guide to diagnosis and management. 4th ed. Mc Graw Hill; 2005.
4. Vincent, T. and Mechti, N. (2005) Extracellular matrix in bone marrow can mediate drug resistance in myeloma. Leuk Lymphoma., 46, 803-11.
5. Uchiyama, H.; Barut, B.A.; Chauhan, D.; Cannistra, S.A. and Anderson, K.C. (1992) Characterization of adhesion molecules on human myeloma cell lines. Blood, 80, 2306-14.
6. Ridley, R.C.; Xiao, H.; Hata, H.; Woodliff, J.; Epstein, J. and Sanderson, R.D. (1993) Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood, 81, 767-74.
7. Aruffo, A.; Stamenkovic, I.; Melnick, M.; Underhill, C.B. and Seed, B. (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell, 61, 1303-13.
8. Pilarski, L.M.; Masellis-Smith, A.; Belch, A.R.; Yang, B.; Savani, R.C. and Turley, E.A. (1994) RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy? Leuk Lymphoma., 14, 363-74.
9. Damiano, J.S.; Cress, A.E.; Hazlehurst, L.A.; Shtil, A.A. and Dalton, W.S. (1999) Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood, 93, 1658-67.
10. Sanz-Rodriguez, F.; Hidalgo, A. and Teixido, J. (2001) Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-mediated multiple myeloma cell adhesion to CS-1/fibronectin and VCAM-1. Blood, 97, 346-51.
11. Damiano, J.S. and Dalton, W.S. (2000) Integrin-mediated drug resistance in multiple myeloma. Leuk Lymphoma., 38, 71-81.
12. Hazlehurst, L.A.; Damiano, J.S.; Buyuksal, I.; Pledger, W.J. and Dalton, W.S. (2000) Adhesion to fibronectin via beta1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene, 19, 4319-27.
13. Landowski, T.H.; Olashaw, N.E.; Agrawal, D. and Dalton, W.S. (2003) Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-kappa B [RelB/p50] in myeloma cells. Oncogene, 22, 2417-21.
14. Basseres, D.S. and Baldwin, A.S. (2006) Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene, 25, 6817-30.
15. Shain, K.H.; Landowski, T.H. and Dalton, W.S. (2002) Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced apoptosis in hematopoietic cancer cell lines. J. Immunol., 168, 2544-53.
16. Vincent, T.; Jourdan, M.; Sy, M.S.; Klein, B. and Mechti, N. (2001) Hyaluronic acid induces survival and proliferation of human myeloma cells through an interleukin-6-mediated pathway involving the phosphorylation of retinoblastoma protein. J. Biol. Chem., 276, 14728-36.
17. Vincent, T.; Molina, L.; Espert, L. and Mechti, N. (2003) Hyaluronan, a major non-protein glycosaminoglycan component of the extracellular matrix in human bone marrow, mediates dexamethasone resistance in multiple myeloma. Br. J. Haematol., 121, 259-69.
18. Sanderson, R.D. and Yang, Y. (2007) Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin. Exp. Metastasis., 25, 149-59.
19. Calabro, A.; Oken, M.M.; Hascall, V.C. and Masellis, A.M. (2002) Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients. Blood, 100, 2578-85.
20. Dahl, I.M.; Turesson, I.; Holmberg, E. and Lilja, K. (1999) Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration. Blood, 93, 4144-8.
21. Paizi, M.; Manaster, J.; Quitt, M. and Spira, G. (1991) High plasma fibronectin levels in multiple myeloma patients: possible mechanisms and clinical implications. Scand. J. Immunol., 34, 285-9.
22. Tokoyoda, K.; Egawa, T.; Sugiyama, T.; Choi, B.I. and Nagasawa, T. (2004) Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity, 20, 707-18.
23. Minges Wols, H.A.; Ippolito, J.A.; Yu, Z.; Palmer, J.L.; White, F.A. and Le, P.T. (2007) The effects of microenvironment and internal programming on plasma cell survival. Int. Immunol., 19, 837-46.
24. Degrassi, A.; Hilbert, D.M.; Rudikoff, S.; Anderson, A.O.; Potter, M. and Coon, H.G. (1993) In vitro culture of primary plasmacytomas requires stromal cell feeder layers. Proc. Natl. Acad. Sci. USA, 90, 2060-4.
25. Grigorieva, I.; Thomas, X. and Epstein, J. (1998) The bone marrow stromal environment is a major factor in myeloma cell resistance to dexamethasone. Exp. Hematol., 26, 597-603.
26. Nefedova, Y.; Landowski, T.H. and Dalton, W.S. (2003) Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms. Leukemia, 17, 1175-82.
27. Uchiyama, H.; Barut, B.A.; Mohrbacher, A.F.; Chauhan, D. and Anderson, K.C. (1993) Adhesion of human myeloma-derived cell lines to bone marrow stromal cells stimulates interleukin-6 secretion. Blood, 82, 3712-20.
28. Van Driel, M.; Gunthert, U.; van Kessel, A.C.; Joling, P.; Stauder, R.; Lokhorst, H.M. and Bloem, A.C. (2002) CD44 variant isoforms are involved in plasma cell adhesion to bone marrow stromal cells. Leukemia, 16, 135-43.
29. Huang, N.; Kawano, M.M.; Mahmoud, M.S.; Mihara, K.; Tsujimoto, T.; Niwa, O. and Kuramoto, A. (1995) Expression of CD21 antigen on myeloma cells and its involvement in their adhesion to bone marrow stromal cells. Blood, 85, 3704-12.
30. Lokhorst, H.M.; Lamme, T.; de Smet, M.; Klein, S.; de Weger, R.A.; van Oers, R. and Bloem, A.C. (1994) Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood, 84, 2269-77.
31. Faid, L.; Van Riet, I.; De Waele, M.; Facon, T.; Schots, R.; Lacor, P. and Van Camp, B. (1996) Adhesive interactions between tumour cells and bone marrow stromal elements in human multiple myeloma. Eur. J. Haematol., 57, 349-58.
32. Chauhan, D.; Uchiyama, H.; Akbarali, Y.; Urashima, M.; Yamamoto, K.; Libermann, T.A. and Anderson, K.C. (1996) Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. Blood, 87, 1104-12.
33. Vincent, T. and Mechti, N. (2004) IL-6 regulates CD44 cell surface expression on human myeloma cells. Leukemia, 18, 967-75.
34. Hideshima, T.; Bergsagel, P.L.; Kuehl, W.M.and Anderson, K.C. (2004) Advances in biology of multiple myeloma: clinical applications. Blood, 104, 607-18.
35. van Driel, M.; Gunthert, U.; Stauder, R.; Joling, P.; Lokhorst, H.M. and Bloem, A.C. (1998) CD44 isoforms distinguish between bone marrow plasma cells from normal individuals and patients with multiple myeloma at different stages of disease. Leukemia, 12, 1821-8.
36. Carter, A.; Merchav, S.; Silvian-Draxler, I. and Tatarsky, I. (1990) The role of interleukin-1 and tumour necrosis factor-alpha in human multiple myeloma. Br. J. Haematol., 74, 424-31.
37. Urashima, M.; Ogata, A.; Chauhan, D.; Hatziyanni, M.; Vidriales, M.B.; Dedera, D.A.; Schlossman, R.L. and Anderson, K.C. (1996) Transforming growth factor-beta1: differential effects on multiple myeloma versus normal B cells. Blood, 87, 1928-38.
38. Bisping, G.; Leo, R.; Wenning, D.; Dankbar, B.; Padro, T.; Kropff, M.; Kröger, M.; Mesters, R.M.; Berdel, W.E.; Kienast, J. (2003) Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood, 101, 2775-83.
39. Dankbar, B.; Padro, T.; Leo, R.; Feldmann, B.; Kropff, M.; Mesters, R.M.; Serve, H.; Berdel, W.E. and Kienast, J. (2000) Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood, 95, 2630-6.
40. Chatterjee, M.; Honemann, D.; Lentzsch, S.; Bommert, K.; Sers, C.; Herrmann, P.; Mathas, S.; Dorken, B. and Bargou, R.C. (2002) In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood, 100, 3311-8.
41. Trikha, M.; Corringham, R.; Klein, B. and Rossi, J.F. (2003) Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin. Cancer Res., 9, 4653-65.
42. Bommert, K.; Bargou, R.C. and Stuhmer, T. (2006) Signalling and survival pathways in multiple myeloma. Eur. J. Cancer, 42, 1574-80.
43. Derksen, P.W.; de Gorter, D.J.; Meijer, H.P.; Bende, R.J.; van Dijk, M.; Lokhorst, H.M.; Bloem, A.C.; Spaargaren, M.; Pals, S.T. (2003) The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma. Leukemia, 17, 764-74.
44. Peacock,, C.D.; Wang, Q.; Gesell, G.S.; Corcoran-Schwartz, I.M.; Jones, E.; Kim, J.; Devereux, W.L.; Rhodes, J.T.; Huff, C.A.; Beachy, P.A.; Watkins, D.N. and Matsui, W. (2007) Hedgehog signaling maintains a tumor stem cell compartment in multiple myeloma. Proc. Natl. Acad. Sci. USA, 104, 4048-53.
45. Dierks, C.; Grbic, J.; Zirlik, K.; Beigi, R.; Englund, N.P.; Guo, G.R.; Veelken, H.; Engelhardt, M.; Mertelsmann, R.; Kelleher, J.F.; Schultz, P. and Warmuth, M. (2007) Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat.Med., 13, 944-51.
46. Nefedova, Y.; Cheng, P.; Alsina, M.; Dalton, W.S. and Gabrilovich, D.I. (2004) Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood, 103, 3503-10.
47. Nefedova, Y.; Sullivan, D.M.;, Bolick. S.C.; Dalton, W.S. and Gabrilovich, D.I. (2008) Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood, 111, 2220-9.
48. Kobune, M.; Chiba, H.; Kato, J.; Kato, K.; Nakamura, K.; Kawano, Y.; Takada, K.; Takimoto, R.; Takayama, T.; Hamada, H.; Niitsu, Y. (2007) Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol. Cancer Ther., 6, 1774-84.
49. Mitsiades, C.S.; Hayden, P.J.; Anderson, K.C. and Richardson, P.G. (2007) From the bench to the bedside: emerging new treatments in multiple myeloma. Best Pract. Res. Clin Haematol., 20, 797-816. javascript:PopUpMenu2_Set(Menu18070720).
50. Anderson, K.C. (2007) Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp. Hematol., 35, 155-62.
51. Garderet, L.; Mazurier, C.; Chapel, A.; Ernou, I.; Boutin, L.; Holy, X.; Gorin, N.C.; Lopez, M.; Doucet, C. and Lataillade, J.J. (2007) Mesenchymal stem cell abnormalities in patients with multiple myeloma. Leuk. Lymphoma., 48, 2032-41.
52. Arnulf, B.; Lecourt, S.; Soulier, J.; Ternaux, B.; Lacassagne, M.N.; Crinquette, A.; Dessoly, J.; Sciaini, A.K.; Benbunan, M.; Chomienne, C.; Fermand, J.P.; Marolleau, J.P. and Larghero, J. (2007) Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia, 21, 158-63.
53. Corre, J.; Mahtouk, K.; Attal, M.; Gadelorge, M.; Huynh, A.; Fleury-Cappellesso, S.; Danho, C.; Laharrague, P.; Klein, B.; Reme, T. and Bourin, P. (2007) Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia, 21, 1079-88.
54. Calabro, A.; Oken, M.M.; Hascall, V.C. and Masellis, A.M. (2002) Characterization of hyaluronan synthase expression and hyaluronan synthesis in bone marrow mesenchymal progenitor cells: predominant expression of HAS1 mRNA and up-regulated hyaluronan synthesis in bone marrow cells derived from multiple myeloma patients. Blood, 100, 2578-85.
55. Esteve, F.R. and Roodman, G.D. (2007) Pathophysiology of myeloma bone disease. Best Pract. Res. Clin. Haematol., 20, 613-24.
56. Cozzolino, F.; Torcia, M.; Aldinucci, D.; Rubartelli, A.; Miliani, A.; Shaw, A.R.; Lansdorp, P.M. and Di Guglielmo, R. (1989) Production of interleukin-1 by bone marrow myeloma cells. Blood, 74, 380-7.
57. Farrugia, A.N.; Atkins, G.J.; To, L.B.; Pan, B.; Horvath, N.; Kostakis, P.; Findlay, D.M.; Bardy, P. and Zannettino, A.C. (2003) Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res., 63, 5438-45.
58. Han, J.H.; Choi, S.J.; Kurihara, N.; Koide, M.; Oba, Y. and Roodman, G.D. (2001) Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand. Blood, 97, 3349-53.
59. Choi, S.J.; Cruz, J.C.; Craig, F.; Chung, H.; Devlin, R.D.; Roodman, G.D. and Alsina, M. (2000) Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood, 96, 671-5.
60. Oba, Y.; Lee, J.W.; Ehrlich, L.A.; Chung, H.Y.; Jelinek, D.F.; Callander, N.S.; Horuk, R.; Choi, S.J.and Roodman, G.D. (2005) MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp. Hematol., 33, 272-8.
61. Uneda, S.; Hata, H.; Matsuno, F.; Harada, N.; Mitsuya, Y.; Kawano, F. and Mitsuya, H. (2003) Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br. J. Haematol., 120, 53-5.
62. Choi, S.J.; Oba, Y.; Gazitt, Y.; Alsina, M.; Cruz, J.; Anderson, J. and Roodman, G.D. (2001) Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J. Clin. Invest., 108, 1833-41.
63. Lee, J.W.; Chung, H.Y.; Ehrlich, L.; Jelinek, D.F.; Callander, N.S.; Roodman, G.D. and Choi, S.J. (2004) IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood, 103, 2308-15.
64. Saeki, Y.; Mima, T.; Ishii, T.; Ogata, A.; Kobayashi, H.; Ohshima, S.; Ishida, T.; Tabunoki, Y.; Kitayama, H.; Mizuki, M.; Katada, Y.; Asaoku, H.; Kitano, M.; Nishimoto, N.; Yoshizaki, K.; Maeda, M.; Kon, S.; Kinoshita, N.; Uede, T. and Kawase, I. (2003) Enhanced production of osteopontin in multiple myeloma: clinical and pathogenic implications. Br. J. Haematol., 123, 263-70.
65. Alexandrakis, M.G.; Passam, F.H.; Sfiridaki, A.; Kandidaki, E.; Roussou, P.; Kyriakou, D. (2003) Elevated serum concentration of hepatocyte growth factor in patients with multiple myeloma: correlation with markers of disease activity. Am. J. Hematol., 72, 229-33.
66. Nakagawa, M.; Kaneda, T.; Arakawa, T.; Morita, S.; Sato, T.; Yomada, T.; Hanada, K.; Kumegawa, M. and Hakeda, Y. (2000) Vascular endothelial growth factor [VEGF] directly enhances osteoclastic bone resorption and survival of mature osteoclasts. FEBS Lett., 473, 161-4.
67. Hecht, M.; von Metzler, I.; Sack, K.; Kaiser, M. and Sezer, O. (2008) Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA). Exp. Cell Res., 314, 1082-93.
68. Yaccoby, S.; Wezeman, M.J.; Henderson, A.; Cottler-Fox, M.; Yi, Q.; Barlogie, B. and Epstein, J. (2004) Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res., 64, 2016-23.
69. Abe, M.; Hiura, K.; Wilde, J.; Shioyasono, A.; Moriyama, K.; Hashimoto, T.; Kido, S.; Oshima, T.; Shibata, H.; Ozaki, S.; Inoue, D. and Matsumoto, T. (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood, 104, 2484-91.
70. Moreaux, J.; Cremer, F.W.; Reme, T.; Raab, M.; Mahtouk, K.; Kaukel, P.; Pantesco, V.; De Vos, J.; Jourdan, E.; Jauch, A.; Legouffe, E.; Moos, M.; Fiol, G.; Goldschmidt, H.; Rossi, J.F.; Hose, D. and Klein, B. (2005) The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature. Blood, 106, 1021-30.
71. Tanaka, Y.; Abe, M.; Hiasa, M.; Oda, A.; Amou, H.; Nakano, A.; Takeuchi, K.; Kitazoe, K.; Kido, S.; Inoue, D.; Moriyama, K.; Hashimoto, T.; Ozaki, S. and Matsumoto, T. (2007) Myeloma cellosteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin. Cancer Res., 13, 816-23.
72. Giuliani, N.; Colla, S.; Sala, R.; Moroni, M.; Lazzaretti, M.; La Monica, S.; Bonomini, S.; Hojden, M.; Sammarelli, G.; Barillè, S.; Bataille, R. and Rizzoli, V. (2002) Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood, 100, 4615-21.
73. Colucci, S.; Brunetti, G.; Rizzi, R.; Zonno, A.; Mori, G.; Colaianni, G.; Del Prete, D.; Faccio, R.; Liso, A.; Capalbo, S.; Liso, V.; Zallone, A. and Grano M. (2004) T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood, 104, 3722-30.
74. Andersen, T.L.; Boissy, P.; Sondergaard, T.E.; Kupisiewicz, K.; Plesner, T.; Rasmussen, T.; Haaber, J.; Kølvraa, S.; Delaissé, J.M. (2007) Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership? J. Pathol., 211, 10-7.
75. Silvestris, F.; Cafforio, P.; Calvani, N. and Dammacco, F. (2004) Impaired osteoblastogenesis in myeloma bone disease: role of upregulated apoptosis by cytokines and malignant plasma cells. Br. J. Haematol., 126, 475-86.
76. Evans, C.E.; Ward, C.; Rathour, L.; Galasko, C.B. (1992) Myeloma affects both the growth and function of human osteoblast-like cells. Clin. Exp. Metastasis, 10, 33-8.
77. Giuliani, N.; Colla, S.; Morandi, F.; Lazzaretti, M.; Sala, R.; Bonomini, S.; Grano, M.; Colucci, S.; Svaldi, M. and Rizzoli, V. (2005) Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood, 106, 2472-83.
78. Li, B.; Shi, M.; Li, J.; Zhang, H.; Chen, B.; Chen, L.; Gao, W.; Giuliani, N. and Zhao, R.C. (2007) Elevated tumor necrosis factor-alpha suppresses TAZ expression and impairs osteogenic potential of Flk-1+ mesenchymal stem cells in patients with multiple myeloma. Stem Cells Dev., 16, 921-30.
79. Ehrlich, L.A.; Chung, H.Y.; Ghobrial, I.; Choi, S.J.; Morandi, F.; Colla, S.; Rizzoli, V.; Roodman, G.D. and Giuliani, N. (2005) IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood, 106, 1407-14.
80. Qiang, Y.W.; Barlogie, B.; Rudikoff, S. and Shaughnessy, J.D. Jr. (2008) Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone, 42, 669-80.
81. Tian, E.; Zhan, F.; Walker, R.; Rasmussen, E.; Ma, Y.; Barlogie, B. and Shaughnessy, J.D. Jr. (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N. Engl. J. Med., 349, 2483-94.
82. Oshima, T.; Abe, M.; Asano, J.; Hara, T.; Kitazoe, K.; Sekimoto, E.; Tanaka, Y.; Shibata, H.; Hashimoto, T.; Ozaki, S.; Kido, S.; Inoue, D. and Matsumoto, T. (2005) Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood, 106, 3160-5.
83. Qiang, Y.W.; Chen, Y.; Stephens, O.; Brown, N.; Chen, B.; Epstein, J.; Barlogie, B. and Shaughnessy, J.D. Jr. (2008) Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma. Blood, 112, 196-207.
84. Bataille, R.; Chappard, D.; Marcelli, C.; Dessauw, P.; Baldet, P.; Sany, J.; Alexandre, C. (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J. Clin. Invest., 88, 62-6.
85. Bataille, R.; Chappard, D.; Marcelli, C.; Rossi, J.F.; Dessauw, P.; Baldet, P.; Sany, J.; Alexandre, C. (1990) Osteoblast stimulation in multiple myeloma lacking lytic bone lesions. Br. J. Haematol., 76, 484-7.
86. Barille, S.; Collette, M.; Bataille, R. and Amiot, M. (1995) Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood, 86, 3151-9.
87. Hecht, M.; Heider, U.; Kaiser, M.; von Metzler, I.; Sterz, J. and Sezer, O. (2007) Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK. Br. J. Haematol., 138, 446-58.
88. Li, X.; Pennisi, A. and Yaccoby, S. (2008) Role of decorin in the antimyeloma effects of osteoblasts. Blood, 112, 159-68.
89. De Raeve, H.; Van Marck, E.; Van Camp, B. and Vanderkerken, K. (2004) Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. Histol. Histopathol., 19, 935-50.
90. Vacca, A.; Ria, R.; Semeraro, F.; Merchionne, F.; Coluccia, M.; Boccarelli, A.; Scavelli, C.; Nico, B.; Gernone, A.; Battelli, F.; Tabilio, A.; Guidolin, D.; Petrucci, M.T.; Ribatti, D. and Dammacco, F. (2003) Endothelial cells in the bone marrow of patients with multiple myeloma. Blood, 102, 3340-8.
91. Jakob, C.; Sterz, J.; Zavrski, I.; Heider, U.; Kleeberg, L.; Fleissner, C.; Kaiser, M. and Sezer, O. (2006) Angiogenesis in multiple myeloma. Eur. J. Cancer, 42, 1581-90.
92. Vacca, A.; Ribatti, D.; Roccaro, A.M.; Ria, R.; Palermo, L. and Dammacco, F. (2001) Bone marrow angiogenesis and plasma cell angiogenic and invasive potential in patients with active multiple myeloma. Acta Haematol., 106, 162-9.
93. Kumar, S.; Witzig, T.E.; Timm, M.; Haug, J.; Wellik, L.; Fonseca, R.; Greipp, P.R. and Rajkumar, S.V. (2003) Expression of VEGF and its receptors by myeloma cells. Leukemia, 17, 2025-31.
94. Bussolino, F.; Di Renzo, M.F.; Ziche, M.; Bocchietto, E.; Olivero, M.; Naldini, L.; Gaudino, G.; Tamagnone, L.; Coffer, A. and Comoglio, P.M. (1992) Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol., 119, 629-41.
95. Colla, S.; Morandi, F.; Lazzaretti, M.; Rizzato, R.; Lunghi, P.; Bonomini, S.; Mancini, C.; Pedrazzoni, M.; Crugnola, M.; Rizzoli, V.; Giuliani, N. (2005) Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia, 19, 2166-76.
96. Pellegrino, A.; Ria, R.; Di Pietro, G.; Cirulli, T.; Surico, G.; Pennisi, A.; Morabito, F.; Ribatti D. and Vacca, A. (2005) Bone marrow endothelial cells in multiple myeloma secrete CXC-chemokines that mediate interactions with plasma cells. Br. J. Haematol., 129, 248-56.
97. Asosingh, K.; Gunthert, U.; Bakkus, M.H.; De Raeve, H.; Goes, E.; Van Riet, I.; Van Camp, B. and Vanderkerken, K(2000). In vivo induction of insulin-like growth factor-I receptor and CD44v6 confers homing and adhesion to murine multiple myeloma cells. Cancer Res., 60, 3096-104.
98. Asosingh, K.; Gunthert, U.; De Raeve, H.; Van Riet, I.; Van Camp, B. and Vanderkerken, K. (2001) A unique pathway in the homing of murine multiple myeloma cells: CD44v10 mediates binding to bone marrow endothelium. Cancer Res., 61, 2862-5.
99. Rigolin, G.M.; Fraulini, C.; Ciccone, M.; Mauro, E.; Bugli, A.M.; De Angeli, C.; Negrini, M.; Cuneo, A. and Castoldi, G. (2006) Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood, 107, 2531-5.
100. Caers, J.; Deleu, S.; Belaid, Z.; De Raeve, H.; Van Valckenborgh, E.; De Bruyne, E.; Defresne, M.P.; Van Riet, I.; Van Camp, B. and Vanderkerken, K. (2007) Neighboring adipocytes participate in the bone marrow microenvironment of multiple myeloma cells. Leukemia, 21, 1580-4.
101. Bahlis, N.J.; King, A.M.; Kolonias, D.; Carlson, L.M.; Liu, H.Y.; Hussein, M.A.; Terebelo, H.R.; Byrne, G.E. Jr.; Levine, B.L.; Boise, L.H. and Lee, K.P. (2007) CD28-mediated regulation of multiple myeloma cell proliferation and survival. Blood, 109, 5002-10.